NCT01903330: ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme |
|
|
| Active, not recruiting | 2 | 84 | US | ERC1671, Gliovac, GM-CSF, Leukine®, sargramostim, Cyclophosphamide, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar, Avastin, MVASI, bevacizumab-awwb, bevacizumab-bvzr, ZIRABEV | Epitopoietic Research Corporation, University of California, Irvine | Glioblastoma, Gliosarcoma | 03/23 | 03/23 | | |
